Roesdi M F, Postma T J, Hoekstra O S, van Groeningen C J, Wolbers J G, Heimans J J
Dept. of Neurology, University Hospital Vrije Universiteit Amsterdam, The Netherlands.
J Neurooncol. 1998 Dec;40(3):251-5. doi: 10.1023/a:1006090807678.
Combination chemotherapy with procarbazine, CCNU and vincristine (PCV) may be effective in patients with recurrent glioma. Response monitoring is mandatory, but radiological response evaluation is often difficult. We evaluated Thallium-201 (201Tl) SPECT as a response parameter in ten patients treated with intensive PCV chemotherapy for recurrent glioma. 201Tl-SPECT studies showed early changes (decreasing volume and intensity) in nine patients and these changes were more pronounced than radiological findings. 201Tl-SPECT results after completion of chemotherapy seemed to correlate with clininal findings during follow up. We conclude that 201Tl-SPECT may contribute to the assessment of response in patients treated with PCV chemotherapy for recurrent glioma.
丙卡巴肼、洛莫司汀和长春新碱（PCV）联合化疗对复发性胶质瘤患者可能有效。必须进行疗效监测，但放射学疗效评估往往很困难。我们评估了201铊（201Tl）单光子发射计算机断层扫描（SPECT）作为10例接受强化PCV化疗的复发性胶质瘤患者的疗效参数。201Tl-SPECT研究显示9例患者有早期变化（体积和强度减小），且这些变化比放射学检查结果更明显。化疗结束后的201Tl-SPECT结果似乎与随访期间的临床发现相关。我们得出结论，201Tl-SPECT可能有助于评估接受PCV化疗的复发性胶质瘤患者的疗效。
